Recruiting NCT06890078
Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biological sampling.
- Who it may be relevant to
- Registry conditions: Pneumocystis, Immunocompromised Patients. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Optimisation du Diagnostic de Pneumocystose Chez Les Patients Immunodéprimés
Overview
Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients
Interventions
- Other Biological sampling
Mouthwash, nasopharyngeal swab, blood sampling
Primary outcome measures
- Pearson correlation coefficient [Time frame: At inclusion]
Secondary outcome measures (3)
- Fungal load by qPCR [Time frame: At inclusion]
- Fungal load by serum PCR [Time frame: At inclusion]
- Beta D glucan blood levels [Time frame: At inclusion]
Eligibility criteria
Inclusion criteria
- adult patients with suspected pneumocystis
- with an indication for bronchial fibroscopy for BAL or induced sputum
- no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition
Exclusion criteria
- Pneumocystis treated for more than 72 hours
- pregnancy/breast-feeding
- adult patients deprived of liberty, protected
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
France · 4 centers
- Hôpital Lariboisière AP-HP Maladies infectieuses — Paris
- Hôpital Saint Louis AP-HP Maladies infectieuses — Paris
- Hôpital Saint Louis AP-HP Réanimation — Paris
- Hôpital Saint-Louis AP-HP Pneumologie — Paris
Identifiers
NCT: NCT06890078 · APHP231319